famotidine has been researched along with Inflammation in 6 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19." | 5.51 | Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial. ( Adnani, H; Brennan, CM; Conigliaro, J; Costa, ASH; Crawford, JM; Demestichas, BR; Dima, RJ; Ferrer, M; Fox, SS; Goldberg, G; Goodwin, S; Ha, T; Janowitz, T; Jordan-Martin, N; Kleeman, SO; Lee, H; Masci, JR; Mourikis, N; Nadella, S; Pili, C; Preall, JB; Prum, S; Rubin, ME; Ryan, MG; Schleicher, CB; Tracey, KJ; Tuveson, DA; von Gablenz, EC; Yang, J; Zhang, X; Zhao, X, 2022) |
| "Gastric ulcer is a multifaceted process including acid secretion, reactive oxygen species generation, prostaglandin inhibition, and extracellular matrix (ECM) degradation." | 5.34 | Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. ( Ganguly, K; Kundu, P; Mishra, A; Pradeepkumar Singh, L; Swarnakar, S, 2007) |
| "Famotidine (FM) is considered among the first-line therapy for treatment of gastric ulcers; however, its poor aqueous solubility resulted in low bioavailability and limited therapeutic efficacy." | 3.96 | Soluplus ( Basha, M; Noshi, SH; Salama, A, 2020) |
| "Gastric ulcer is a multifaceted process including acid secretion, reactive oxygen species generation, prostaglandin inhibition, and extracellular matrix (ECM) degradation." | 1.34 | Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. ( Ganguly, K; Kundu, P; Mishra, A; Pradeepkumar Singh, L; Swarnakar, S, 2007) |
| "Famotidine (FAM) is an H2-antagonist for which the propensity for idiosyncratic reactions is far less than RAN." | 1.32 | Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. ( Cockerell, GL; Cosma, GN; Ganey, PE; Luyendyk, JP; Maddox, JF; Roth, RA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 1 |
| Fan, P | 1 |
| Liu, M | 1 |
| Weng, C | 1 |
| Fan, G | 1 |
| Zhang, T | 1 |
| Duan, X | 1 |
| Wu, Y | 1 |
| Tang, L | 1 |
| Yang, G | 1 |
| Liu, Y | 1 |
| Brennan, CM | 1 |
| Nadella, S | 1 |
| Zhao, X | 1 |
| Dima, RJ | 1 |
| Jordan-Martin, N | 1 |
| Demestichas, BR | 1 |
| Kleeman, SO | 1 |
| Ferrer, M | 1 |
| von Gablenz, EC | 1 |
| Mourikis, N | 1 |
| Rubin, ME | 1 |
| Adnani, H | 1 |
| Lee, H | 1 |
| Ha, T | 1 |
| Prum, S | 1 |
| Schleicher, CB | 1 |
| Fox, SS | 1 |
| Ryan, MG | 1 |
| Pili, C | 1 |
| Goldberg, G | 1 |
| Crawford, JM | 1 |
| Goodwin, S | 1 |
| Zhang, X | 1 |
| Preall, JB | 1 |
| Costa, ASH | 1 |
| Conigliaro, J | 1 |
| Masci, JR | 1 |
| Yang, J | 1 |
| Tuveson, DA | 1 |
| Tracey, KJ | 1 |
| Janowitz, T | 1 |
| Basha, M | 1 |
| Salama, A | 1 |
| Noshi, SH | 1 |
| Luyendyk, JP | 2 |
| Maddox, JF | 1 |
| Cosma, GN | 1 |
| Ganey, PE | 2 |
| Cockerell, GL | 1 |
| Roth, RA | 2 |
| Pradeepkumar Singh, L | 1 |
| Kundu, P | 1 |
| Ganguly, K | 1 |
| Mishra, A | 1 |
| Swarnakar, S | 1 |
| Tukov, FF | 1 |
1 trial available for famotidine and Inflammation
| Article | Year |
|---|---|
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial.
Topics: Adult; COVID-19 Drug Treatment; Double-Blind Method; Famotidine; Female; Humans; Inflammation; SARS- | 2022 |
5 other studies available for famotidine and Inflammation
| Article | Year |
|---|---|
Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells.
Topics: Anti-Ulcer Agents; Cell Line, Tumor; Famotidine; Histamine H2 Antagonists; Humans; Inflammasomes; In | 2021 |
Soluplus
Topics: Animals; Chemistry, Pharmaceutical; Drug Compounding; Excipients; Famotidine; Inflammation; Male; Po | 2020 |
Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats.
Topics: Animals; Anti-Ulcer Agents; Chemical and Drug Induced Liver Injury; Famotidine; Inflammation; Lipopo | 2003 |
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.
Topics: Acute Disease; Animals; Anti-Ulcer Agents; Cytokines; Disease Models, Animal; Ethanol; Famotidine; G | 2007 |
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury.
Topics: Animals; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chemokine CXCL2; Coculture Techniq | 2007 |